

Company Overview

We are a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid drug conjugate™ (PDCs™) delivery platform to develop PDCs that specifically target cancer cells to deliver improved efficacy and better safety as a result of fewer off-target effects. The PDC™ platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments and we plan to develop PDCs independently and through research and development collaborations.

Cellecstar Announces Overall Survival Exceeding 19 Months in Phase 1b Trial with CLR 131 in Relapsed/Refractory Multiple Myeloma

Oct 2 2018, 8:00 AM EDT

Cellecstar Biosciences to Present at the Ladenburg Thalmann 2018 Healthcare Conference

Sep 27 2018, 8:30 AM EDT

Cellecstar's CLR 131 Receives FDA Orphan Drug Designation for the Treatment of Pediatric Osteosarcoma

Sep 25 2018, 8:30 AM EDT

Stock Overview

Symbol	CLRB
Exchange	Nasdaq
Market Cap	10.44m
Last Price	\$2.75
52-Week	\$2.025 - \$18.200001

10/16/2018 04:00 PM EDT

Investor Relations

LHA Investor Relations
Miriam Weber Miller
T: 212-838-3777
MMiller@lhai.com

Management Team

James Caruso

President, CEO and Director

Dr. John Friend

Chief Medical Officer

Jarrold Longcor

Chief Business Officer

Brian M. Posner

Chief Financial Officer

Cellecstar Biosciences, Inc.

8383 Greenway Blvd, Suite 600
Middleton, WI 53562

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.